Major Histocompatibility Complex Binding, Eluted Ligands, and Immunogenicity: Benchmark Testing and Predictions.

Area of Science:

• Immunology
• Pharmacology
• Computational Biology

Background:

• Antidrug antibody (ADA) responses critically influence drug safety, potency, and efficacy.
• ADA responses are often linked to human leukocyte antigen (HLA) class II-restricted CD4+ T-cell reactivity.
• Predicting or measuring CD4+ T-cell reactivity is a key strategy for addressing ADA and immunogenicity concerns.

Purpose of the Study:

• To provide guidance on the relative merits of different methodologies for predicting T-cell reactivity.
• To clarify the outcomes being considered when assessing prediction accuracy.
• To highlight knowledge gaps and areas for future experimental investigation.

Main Methods:

• Analysis of three interconnected variables: major histocompatibility complex (MHC) binding, natural HLA ligand generation, and T-cell immunogenicity.
• Review of methodologies used to predict or measure the capacity of peptides to bind or be natural ligands of HLA class II.
• Emphasis on rigorous benchmarking with fair, objective, and transparent experimental criteria.

Main Results:

• The accuracy of HLA binding predictions is dependent on the specific outcome being predicted (binding, natural processing, or T-cell immunogenicity).
• Different variables and methodologies offer varying predictive power for different outcomes.
• The review provides a perspective on the predictive capabilities of various approaches.

Conclusions:

• Accurate prediction of T-cell reactivity requires clear definition of outcomes and rigorous, experimentally grounded benchmarking.
• Understanding the interplay between HLA binding, natural ligand generation, and T-cell immunogenicity is crucial for predicting ADA development.
• Further experimental work is needed to address identified knowledge gaps in predicting immunogenicity.